Ozempic Side Effects in Women: A Complete, Evidence-Based Guide

Most of what is written about Ozempic side effects is written for everyone. But several of the effects that matter most to women — changes to the menstrual cycle, how a GLP-1 interacts with PCOS, fertility and the so-called “Ozempic babies,” whether it weakens birth control, how it overlaps with menopause and HRT, effects on libido and hair, and what happens to your body after stopping — are female-specific and easy to miss. Women made up roughly three quarters of participants in the pivotal STEP-1 semaglutide trial (Wilding 2021^[1]), yet the women-specific angles are rarely organized in one place. This hub does that: a brief, honest summary of each women-relevant effect, with a link out to our detailed evidence article on each. A quick note on names — “Ozempic” is semaglutide; the same biology applies to Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), and other GLP-1 medications, so we use the terms loosely here.

1. Menstrual cycle changes

Many women notice their periods change after starting a GLP-1 — cycles can become more regular, heavier or lighter, or temporarily irregular. For women with infrequent or absent periods driven by excess weight or PCOS, the most common pattern is that cycles become more regular as weight comes down, because weight loss lowers insulin resistance and restores more normal ovulation. A meta-analysis in PCOS found GLP-1 receptor agonists improved menstrual cyclicity (Zhou 2023^[4]), and a randomized trial of metformin plus semaglutide reported improved menstrual frequency alongside weight loss (Chen 2025^[15]). The change is generally an indirect, weight-and-hormone-mediated effect rather than a direct drug action on the uterus. Our detailed guide on GLP-1 and the menstrual cycle covers the mechanisms, timelines, and what is and is not expected.

2. PCOS: androgens, ovulation, and fertility

Polycystic ovary syndrome is tightly linked to insulin resistance and excess weight, so GLP-1 medications are increasingly used (off-label) in women with PCOS and obesity. The 2023 International PCOS Guideline notes that anti-obesity medications including GLP-1 receptor agonists can be considered for weight management in PCOS (Teede 2023^[6]), and a systematic review prepared for that guideline found these agents reduce weight and improve metabolic markers in PCOS (Goldberg 2024^[7]). As weight falls, ovulation and menstrual regularity often improve, which is why some women conceive unexpectedly — the “Ozempic babies” phenomenon. Reviews specifically frame GLP-1 receptor agonists as a new avenue in obesity, PCOS, and infertility (Cena 2020^[5]). See our deep dives on GLP-1 for PCOS and PCOS, fertility, and pregnancy.

3. Birth control and the pregnancy-avoidance rule

This is the single most important safety point for women of reproductive age. Two things stack: GLP-1 medications can improve fertility (above), and the delayed gastric emptying they cause may reduce the absorption of oral contraceptives. The tirzepatide (Mounjaro/Zepbound) label specifically warns that oral contraceptives may be less effective and advises a backup or non-oral method around dose initiation and escalation; pharmacokinetic reviews of GLP-1 agents discuss this delayed-absorption interaction (Min 2025^[9]). Equally important, GLP-1 medications are not recommended in pregnancy and should be stopped before trying to conceive — manufacturers advise discontinuing about two months ahead because of the long washout. The practical rule: use reliable, ideally non-oral, contraception while on a GLP-1, and plan a deliberate stop if pregnancy is the goal. Full detail is in our GLP-1 and birth control safety guide.

4. Menopause, perimenopause, and HRT overlap

Weight gain and a shift toward abdominal fat are common around the menopausal transition, and many women start a GLP-1 during perimenopause or after. GLP-1 medications work the same way regardless of menopausal status, but two overlaps matter. First, hormone therapy (HRT/MHT) and a GLP-1 are not mutually exclusive — they address different problems, and decisions about menopausal hormone therapy follow their own risk-benefit framework (NAMS 2022^[16]). Second, perimenopausal hormonal swings can make tracking which symptom comes from which intervention harder. We cover both the body-composition and the hormone-overlap questions in our guides on GLP-1, menopause, and HRT and GLP-1 in perimenopause.

5. Libido and sexual function

Effects on sex drive are mixed and individual. Weight loss itself often improves sexual function and self-image, and in women with PCOS — a group with documented higher rates of sexual dysfunction (Pastoor 2024^[14]) — improvements in metabolic and hormonal status may help. On the other hand, some women report lower libido on a GLP-1, which may relate to fatigue, reduced food-related reward, body-image shifts during rapid change, or relationship factors rather than a direct hormonal effect. The evidence here is early and not GLP-1-specific. Our article on semaglutide and sex drive in women weighs what is known, and our pages on genital fat-loss changes and breast changes cover the body-region effects that can accompany large weight loss.

6. Hair loss (telogen effluvium)

Hair shedding after starting a GLP-1 is common, distressing, and almost always a form of telogen effluvium — a temporary, diffuse shedding triggered by the physiological stress of rapid weight loss and reduced calorie and protein intake, not a toxic effect on the follicle (Hughes 2026^[11]). The same pattern is well documented after bariatric surgery and other fast weight loss (Cohen-Kurzrock 2021^[12]), and it appeared as a reported adverse event in tirzepatide body-composition data (Look 2025^[10]). It typically begins a couple of months after the trigger, peaks, and then recovers as weight stabilizes; adequate protein and correcting iron or other deficiencies help. Women, who more often notice diffuse thinning, are disproportionately affected. Full detail in our Ozempic hair loss guide.

7. Nausea, fatigue, and the common GI effects, as they affect women

The everyday side effects — nausea, vomiting, constipation, diarrhea, and fatigue — are the same for everyone, but a few things make them women-relevant. They are the most common adverse events overall — nausea, diarrhea, and constipation led the adverse-event profile in the pivotal tirzepatide obesity trial (Jastreboff 2022^[2]) — and in the dedicated tolerability analysis of semaglutide 2.4 mg, gastrointestinal events were typically mild to moderate, most frequent during dose escalation, and tended to settle over time (Wharton 2022^[3]). Because doses are not weight-adjusted, women, who on average have lower body weight, can experience these effects more intensely at the same milligram dose, and nausea can collide with the appetite suppression to make hitting protein targets (the thing that protects muscle and hair) harder. Slower titration, smaller protein-forward meals, and hydration are the standard levers.

8. After stopping: rebound appetite and weight regain

One of the most searched women's questions is what happens after stopping. The honest answer from the trial data: appetite returns and a large share of the lost weight tends to come back. In the STEP-4 randomized trial, participants switched to placebo after the titration phase regained weight, while those who continued semaglutide kept losing (Rubino 2021^[13]). Stopping is sometimes necessary — most importantly, GLP-1 medications should be stopped before pregnancy — but it should be planned, ideally with lifestyle and resistance-training scaffolding to blunt the regain, and sometimes a tapering or maintenance strategy discussed with a prescriber. There is also PCOS-specific evidence that some weight maintenance is possible with continued metformin after semaglutide withdrawal (Jensterle 2024^[8]). Our guides on rebound appetite after stopping and preventing the snap-back cover the strategy in full.

When to call your clinician

Most side effects are mild and self-limited, but some warrant prompt contact: severe or persistent abdominal pain (possible pancreatitis or gallbladder problems), signs of dehydration from prolonged vomiting or diarrhea, a confirmed or suspected pregnancy, or any new severe symptom. Hair shedding, mild nausea, and menstrual changes are usually managed conservatively but are worth mentioning at a routine visit so deficiencies can be checked.

Bottom line

• The general GLP-1 side effects (nausea, vomiting, constipation, fatigue) affect women the same way as everyone, but lower average body weight at the same milligram dose can make them feel more intense.
• The women-specific effects are the ones to plan around: menstrual change, PCOS and restored fertility, reduced reliability of oral birth control, menopause/HRT overlap, libido shifts, and temporary hair shedding.
• The two highest-stakes points: use reliable (ideally non-oral) contraception on a GLP-1, and stop the medication before pregnancy.
• After stopping, appetite returns and weight regain is common — a planned exit with lifestyle support matters.
• This hub is an orientation; follow the linked detailed article for each topic, where the full evidence and citations live.

Related research

• GLP-1 and the menstrual cycle — how and why periods change.
• GLP-1 for PCOS — androgens, ovulation, and metabolic effects.
• GLP-1, pregnancy, fertility, and PCOS — the “Ozempic babies” question.
• GLP-1 and birth control — the contraception and pregnancy-avoidance rules.
• GLP-1, menopause, and HRT — the hormone-therapy overlap.
• GLP-1 in perimenopause — weight loss during the transition.
• Semaglutide and sex drive in women — libido and sexual function.
• Ozempic hair loss — telogen effluvium and recovery.
• Genital fat-loss changes — body-region effects of large weight loss.
• Breast changes — what happens to breast tissue.
• Rebound appetite after stopping — the biology of regain.
• Preventing the snap-back — planning your exit.

Important disclaimer. This article is educational and does not constitute medical advice. GLP-1 medications are prescription drugs; decisions about starting, dosing, combining with hormone therapy or contraception, or stopping should be made with a qualified clinician who knows your history. The pregnancy-avoidance guidance is general - confirm specifics with your prescriber and the product label. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-19.